長江健康(002435.SZ)旗下長江醫藥投資收到仲裁申請書 涉及山東華信製藥股份轉讓協議引起的爭議
格隆匯11月25日丨長江健康(002435.SZ)公佈，公司全資子公司長江潤髮張家港保税區醫藥投資有限公司(“長江醫藥投資”、被申請人)於近日收到北京仲裁委員會送達的仲裁申請書、答辯通知等仲裁材料，具體情況如下：
此次仲裁的申請人馬俊華由於合同糾紛向北京仲裁委員會遞交了仲裁申請書，北京仲裁委員會向長江醫藥投資送達了仲裁申請書、關於(2019)京仲案字第5640號仲裁案答辯通知等仲裁材料。
仲裁事項的背景情況：2018年7月14日，申請人馬俊華、被申請人長江潤髮張家港保税區醫藥投資有限公司以及案外人劉瑞環、王萍、上海和儒投資管理中心(有限合夥)簽署了《山東華信製藥集團股份有限公司股份轉讓協議》，協議約定：馬俊華向長江醫藥投資轉讓其所持山東華信製藥集團股份有限公司(“山東華信製藥”)3013.8852萬股股份，股權轉讓價格約人民幣8.41億元，分階段有條件支付。根據協議約定，被申請人應向申請人支付股份轉讓價款約1.40億元，但被申請人僅於2019年9月2日向申請人支付股份轉讓款3000萬元。
仲裁請求：申請人馬俊華因與被申請人長江醫藥投資簽訂的《山東華信製藥集團股份有限公司股份轉讓協議》所引起的爭議提出以下仲裁請求：
1、裁決被申請人向申請人支付(2018年度應付)股份轉讓價款人民幣約1.10億元整；
2、裁決被申請人向申請人返還山東華信製藥集團股份有限公司1004.6296萬股股份(佔山東華信製藥集團股份有限公司全部股份的18.0867%，對應價值約2.80億元)；
3、裁決被申請人自2018年5月24日起向申請人支付違約金，違約金支付至實際付款日(截止2019年9月22日，違約金為818.04萬元)；
4、裁決被申請人向申請人支付律師費110萬元；
5、裁決被申請人承擔仲裁費。
本案已由北京仲裁委員會受理，目前尚未開庭審理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
